AGIOS PHARMACEUTICALS ($AGIO) posted quarterly earnings results for Q3 2026 on Thursday, November 5th. The company reported earnings of -$1.09 per share, beating estimates of -$1.25 by $0.16. The company also reported revenue of $55,390,000, beating estimates of $54,272,262 by $1,117,738.
You can see Quiver Quantitative's $AGIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AGIOS PHARMACEUTICALS Insider Trading Activity
AGIOS PHARMACEUTICALS insiders have traded $AGIO stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $AGIO stock by insiders over the last 6 months:
- SARAH GHEUENS (Chief Medical Officer) has made 0 purchases and 4 sales selling 39,855 shares for an estimated $1,285,511.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
AGIOS PHARMACEUTICALS Hedge Fund Activity
We have seen 135 institutional investors add shares of AGIOS PHARMACEUTICALS stock to their portfolio, and 89 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ASSENAGON ASSET MANAGEMENT S.A. added 1,782,457 shares (+1714.6%) to their portfolio in Q3 2026, for an estimated $59,266,695
- MPM BIOIMPACT LLC removed 1,306,261 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $48,475,345
- D. E. SHAW & CO., INC. added 1,269,819 shares (+69.1%) to their portfolio in Q2 2026, for an estimated $47,122,983
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,256,080 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $46,613,128
- ADAR1 CAPITAL MANAGEMENT, LLC added 1,147,381 shares (+815.6%) to their portfolio in Q2 2026, for an estimated $42,579,308
- UBS GROUP AG added 853,291 shares (+643.8%) to their portfolio in Q2 2026, for an estimated $31,665,629
- BLACKROCK, INC. added 701,040 shares (+12.2%) to their portfolio in Q2 2026, for an estimated $26,015,594
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
AGIOS PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $AGIO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AGIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 08/20.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
AGIOS PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $AGIO recently. We have seen 5 analysts offer price targets for $AGIO in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Gregory Renza from Truist Securities set a target price of $41.0 on 07/07/2026
- Alec Stranahan from B of A Securities set a target price of $46.0 on 07/07/2026
- Luca Issi from RBC Capital set a target price of $32.0 on 07/07/2026
- Tessa Romero from JP Morgan set a target price of $31.0 on 06/11/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
